What is the ticker symbol for Coya Therapeutics?

Coya Therapeutics trades under the ticker COYA on NASDAQ.

What sector does Coya Therapeutics operate in?

Coya Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze COYA in a portfolio?

PortView shows COYA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Coya Therapeutics (COYA) Stock Analysis

NASDAQHealthcareBiotechnology

$4.45-1.33%

1-year price historyRange $3.78 – $7.36

52-week range$4.45

$3.71$7.75

What Coya Therapeutics does

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Key metrics

Market cap

$104.38M

P/E (TTM)

-4.28

EPS (TTM)

$-1.04

Beta

0.60

Dividend yield

0.00%

Revenue / share

$0.34

50-day avg

$4.85

200-day avg

$4.88

52-week high

$7.75

52-week low

$3.71

CEO

Arun Swaminathan

ETFs linked to COYA

Broad-market and Healthcare sector ETFs an investor holding Coya Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how COYA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze COYA in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Coya Therapeutics?: Coya Therapeutics trades under the ticker COYA on NASDAQ.
Which exchange is COYA listed on?: COYA is listed on NASDAQ.
What sector does Coya Therapeutics operate in?: Coya Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze COYA in a portfolio?: PortView shows COYA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.